Physician profile
Deepthi Naik
NPI 1962885368
$1,636.07
in general payments reported to CMS, 2019-2025
16 companies · $19.97 in 2025
The $19.97 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $67.72 · 2021: $15.97 · 2024: $135 · 2025: $19.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $334.69 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $303.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.48 | 2019 | |
| Amgen INC. | $123.77 | 2019 | |
| Abbvie INC. | $123.39 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $121.30 | 2019 | |
| Amarin Pharma, INC. | $117.74 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $93.88 | 2019 | |
| Merck Sharp & Dohme LLC | $62.18 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $57.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.32 | 2019 | |
| Allergan, INC. | $30.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.77 | 2019 | |
| Pfizer INC. | $14.59 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Metuchen Pharmaceuticals | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthi Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.